Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab


  • Anthony HowellEmail author
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_2276-2



Fulvestrant was originally known as ICI 182,780 and is now marketed by AstraZeneca under the trade name Faslodex®. The chemical formula of fulvestrant is 7α-[9-(4,4,5,5,5-pentafluoro-pentylsulfinyl)nonyl]estra-1,3,5(10)-triene-3,17β-diol.

Fulvestrant, a steroidal 7α-alkylsulfinyl analog of 17β-estradiol, is an estrogen receptor antagonist with no agonist effects. It is used as an endocrine treatment for postmenopausal women with hormone-sensitive advanced breast cancer.


Mode of Action

Currently, more than one million women worldwide are diagnosed with breast cancer each year. In postmenopausal women, approximately 75 % of breast tumors are hormone sensitive, expressing the estrogen receptor and/or progesterone receptor, and are stimulated to grow in the presence of estrogen. To understand the treatments for hormone receptor-positive breast cancer, we must first understand the role of estrogen, a natural circulating hormone that has been...


Estrogen Receptor Aromatase Inhibitor Advanced Breast Cancer Partial Agonist Activity Estrogen Receptor Antagonist 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.


  1. Chia S, Gradishar W, Mavriac L et al (2008) Double-blind, randomized, placebo-controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol. Published online a head of print 3 Mar 2008 at http://jco.ascopubs.orglcgi/doi/10.1200/jco.2007.13.5822
  2. Dowsett M, Nicholson RI, Pietras RJ (2005) Biological characteristics of the pure antiestrogen fulvestrant: overcoming endocrine resistance. Breast Cancer Res Treat 93(Suppl 1):S11–S18CrossRefPubMedGoogle Scholar
  3. Howell A (2005) Fulvestrant (‘Faslodex’): current and future role in breast cancer management. Crit Rev Oncol Hematol 57:265–273CrossRefGoogle Scholar
  4. Robertson JF, Osborne CK, Howell A et al (2003) Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women – a prospective combined analysis of two multicenter trials. Cancer 98:229–238CrossRefPubMedGoogle Scholar
  5. Vergote I, Abram P (2006) Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents. Ann Oncol 17:200–204CrossRefPubMedGoogle Scholar

See Also

  1. (2012) Advanced Breast Cancer. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 100. doi: 10.1007/978-3-642-16483-5_128Google Scholar
  2. (2012) Antiestrogens. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 209. doi: 10.1007/978-3-642-16483-5_318Google Scholar
  3. (2012) EGF. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 1211. doi: 10.1007/978-3-642-16483-5_1824Google Scholar
  4. (2012) Estrogens. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 1333. doi: 10.1007/978-3-642-16483-5_2019Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.CRUK Department of Medical OncologyUniversity of Manchester, Christie Hospital NHS TrustManchesterUK